These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10027321)

  • 21. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer.
    Tierney GM; Griffin NR; Stuart RC; Kasem H; Lynch KP; Lury JT; Brown PD; Millar AW; Steele RJ; Parsons SL
    Eur J Cancer; 1999 Apr; 35(4):563-8. PubMed ID: 10492628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low-dose iloprost. An open pilot study.
    Banyai S; Jenelten R; Wagner S; Allmann J; Banyai M; Koppensteiner R
    Int Angiol; 2002 Mar; 21(1):36-43. PubMed ID: 11941272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
    Levitt NC; Eskens FA; O'Byrne KJ; Propper DJ; Denis LJ; Owen SJ; Choi L; Foekens JA; Wilner S; Wood JM; Nakajima M; Talbot DC; Steward WP; Harris AL; Verweij J
    Clin Cancer Res; 2001 Jul; 7(7):1912-22. PubMed ID: 11448904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer.
    Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(44):388-92. PubMed ID: 11995458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.
    Fujiwara Y; Yamamoto N; Yamada Y; Yamada K; Otsuki T; Kanazu S; Iwasa T; Hardwick JS; Tamura T
    Cancer Sci; 2009 Sep; 100(9):1728-34. PubMed ID: 19575752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
    Baldi F; Morselli-Labate AM; Cappiello R; Ghersi S;
    Am J Gastroenterol; 2002 Jun; 97(6):1357-64. PubMed ID: 12094850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NTP Toxicology and Carcinogenesis Studies of Promethazine Hydrochloride (CAS No. 58-33-3) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Dec; 425():1-272. PubMed ID: 12616286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
    Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
    BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid.
    Eatock M; Cassidy J; Johnson J; Morrison R; Devlin M; Blackey R; Owen S; Choi L; Twelves C
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):39-46. PubMed ID: 15368080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.
    Shepherd FA; Giaccone G; Seymour L; Debruyne C; Bezjak A; Hirsh V; Smylie M; Rubin S; Martins H; Lamont A; Krzakowski M; Sadura A; Zee B
    J Clin Oncol; 2002 Nov; 20(22):4434-9. PubMed ID: 12431965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers.
    Millar AW; Brown PD; Moore J; Galloway WA; Cornish AG; Lenehan TJ; Lynch KP
    Br J Clin Pharmacol; 1998 Jan; 45(1):21-6. PubMed ID: 9489589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Early judgement on the results in radiation therapy of colorectal cancer: determination of carcinoembryonic antigen (CEA) in blood serum at daily intervals from the beginning of irradiation (author's transl)].
    Pompecki R; Schleusner V; Ziegler HW; Winkler R; Rehpenning W
    Strahlentherapie; 1981 Feb; 157(2):81-5. PubMed ID: 7222135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy.
    Toppmeyer DL; Gounder M; Much J; Musanti R; Vyas V; Medina M; Orlando T; Pennick M; Lin Y; Shih W; Goodin S; Rubin E
    Med Sci Monit; 2003 Aug; 9(8):PI99-104. PubMed ID: 12942041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [High levels of carcinoembryonic antigen (CEA) in the serum of uremic patients under hemodialysis treatment].
    Docci D; Turci F; Pistocchi E
    Quad Sclavo Diagn; 1984 Dec; 20(4):435-9. PubMed ID: 6537552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.